首页> 美国卫生研究院文献>Journal of Medical Case Reports >A novel combination of bortezomib lenalidomide and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report
【2h】

A novel combination of bortezomib lenalidomide and clarithromycin produced stringent complete response in refractory multiple myeloma complicated with diabetes mellitus – clinical significance and possible mechanisms: a case report

机译:硼替佐米来那度胺和克拉霉素的新型组合在难治性多发性骨髓瘤并发糖尿病中产生严格的完全反应-临床意义和可能的机制:一例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundIn general, dexamethasone is a required component drug in various combination chemotherapies for treating multiple myeloma, and its efficacy has been widely recognized. However, administration of dexamethasone is known to cause various adverse effects including hyperglycemia which requires insulin therapy. During the course of treatment, we developed a novel effective dexamethasone-free combination regimen and evaluated it for its effect in multiple myeloma.
机译:背景技术通常,地塞米松是用于治疗多发性骨髓瘤的各种组合化学疗法中必需的成分药物,并且其功效已被广泛认可。但是,已知地塞米松的给药会引起各种不良反应,包括需要胰岛素治疗的高血糖症。在治疗过程中,我们开发了一种新型的有效地塞米松无联合疗法,并对其在多发性骨髓瘤中的作用进行了评估。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号